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Abstract
Large commercial laboratories in the United States were surveyed regarding the number of 
specimens tested for eight tickborne diseases in 2008. Seven large commercial laboratories 
reported testing a total of 2,927,881 specimens nationally (including Lyme disease). Of these, 
495,585 specimens (17 percent) were tested for tickborne diseases other than Lyme disease. In 
addition to large commercial laboratories, another 1,051 smaller commercial, hospital, and 
government laboratories in four states (CT, MD, MN, and NY) were surveyed regarding tickborne 
disease testing frequency, practices, and results. Ninety-two of these reported testing a total of 
10,091 specimens for four tickborne diseases other than Lyme disease. We estimate the cost of 
laboratory diagnostic testing for non-Lyme disease tickborne diseases in 2008 to be $9.6 million. 
These data provide a baseline to evaluate trends in tickborne disease test utilization and insight 
into the burden of these diseases.
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North American ticks transmit the agents of Lyme disease and several other tickborne 
diseases (TBDs) of humans. Although the geographic distributions of specific diseases vary, 
TBDs occur throughout the United States and collectively constitute a public health 
problem. Overall reports of TBDs have increased over the last decade, possibly reflecting 
greater exposure, increased awareness, improved diagnostics, changes in surveillance 
practices, changes in human activities, and variation in tick distributions and infection 
prevalence.
Laboratory testing can be central to establishing the correct diagnosis and guiding care for 
patients with TBDs, including those with atypical presentations. Alternatively, testing 
specimens from patients with a low disease probability can lead to misinterpretation of 
positive results and inflate medical costs (Ramsey et al., 2004). The number of Lyme disease 
tests performed in 1995 was estimated at 2.8 million using marketing data (MK Associates, 
1993; Tugwell et al., 1997); however, the current volume of testing for Lyme and other 
TBDs is expected to be much higher (Hinckley et al, 2014).
In an effort to better understand TBD diagnostic testing practice and volume, a nationwide 
survey of large commercial laboratories was conducted, as well as hospital-based and other 
smaller laboratories in four states where Lyme and other tick-borne diseases are endemic. In 
addition, we used the reported volume to estimate the cost of non-Lyme disease TBD testing 
in the United States.
MATERIAL AND METHODS
TickNET is a network created in 2007 to foster collaboration on surveillance, research, 
education, and prevention for tickborne diseases. Collaborators include various divisions 
within CDC and key state and local health departments. CDC provides extramural funding 
to participating health departments and partners through the Epidemiology and Laboratory 
Capacity for Infectious Diseases cooperative agreement, to sustain and enhance surveillance 
for Lyme disease, and through the Emerging Infections Program (EIP), to promote applied 
research. There are EIPs are located within Connecticut, Maryland, Minnesota, and New 
York,, and Lyme disease cases in these four states accounted for nearly 40 percent of all 
reported cases in the United States in 2008. In addition, 56 percent of HGA cases, 14 percent 
of HME cases, and 5 percent of RMSF were reported from these four states in 2008 (CDC, 
2010). At the time of this study, Babesia infection was not nationally notifiable so the 
endemnicity of babesiosis compared to other US states could not be compared. However, in 
2011, more than 50 percent of the 1,124 confirmed and probable cases of babesiosis were 
reported from Connecticut, Minnesota, and New York (CDC, 2011). The etiologic agents of 
Lyme disease, HGA, and babesiosis are all transmitted by the blacklegged tick (Ixodes 
scapularis).
In an effort to better understand TBD diagnostic testing practice and volume, a survey of 
large commercial laboratories as well as hospital-based and other smaller laboratories was 
conducted in four TickNET states. A two-phased approach was used (Figure 1). The 
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catchment area for this study included laboratories that were likely to test patients in 
Connecticut, Maryland, Minnesota, and New York, as determined by state and national 
disease surveillance records. The survey included commercial laboratories (Phase 1) and 
smaller clinical and hospital-based laboratories (Phase 2) that were likely to test patients for 
TBDs, as determined by a review of state disease surveillance records.
Phase 1
The first phase of the survey was aimed at large commercial laboratories known to conduct 
TBD disease testing nationally. The following laboratories were contacted by email and 
telephone to ask for participation: ARUP, Clinical Laboratory Partners, Focus Diagnostics, 
Laboratory Corporation of America (LabCorp), Mayo Medical Laboratories, Quest 
Diagnostics, and Specialty Laboratories. These laboratories accounted for the majority of 
Lyme disease cases reported to health departments in the four endemic states (Connecticut, 
Maryland, Minnesota and New York) in 2008. Three additional laboratories known to 
provide alternative non-FDA approved methods of Lyme disease testing (IGeneX, MD 
Laboratories, Neuroimmunology Laboratory) were also contacted and asked to participate. 
The survey was sent to laboratories by email and returned by fax or email. Non-responding 
laboratories were contacted by phone and email by EIP or CDC research staff on a minimum 
of three occasions to request participation. Commercial laboratories were asked to report 
their national specimen testing volume for eight TBDs (Lyme disease, RMSF, babesiosis, 
HGA, HME, tickborne relapsing fever, Colorado tick fever, and Powassan virus); because 
single specimens may have been tested for multiple pathogens and single patients could 
have multiple specimens submitted, the number of specimens tested does not necessarily 
reflect the number of patients tested. In addition, it is possible that one specimen may have 
been tested for one pathogen by more than one assay.
Phase 2
The second phase of the survey targeted clinical, hospital, government, and small 
commercial laboratories in the four TickNET states. State health department surveillance 
records in Connecticut, Maryland, and Minnesota were reviewed to identify laboratories that 
were known to conduct TBD testing. In New York, all licensed laboratories were surveyed 
regardless of whether or not they were known to conduct TBD testing. Identified 
laboratories were asked to complete an emailed survey regarding the number of tests and 
types of assays performed by their laboratory in 2008 for eight TBDs. As with the Phase 1 
survey, laboratories reported the total specimens tested. Therefore, because single specimens 
may have been tested for multiple pathogens and single patients could have multiple 
specimens submitted, the number of specimens tested does not necessarily reflect the 
number of patients tested.
Respondents to Phase 2 were asked to report the percent positive by diagnostic assay for 
residents of the four endemic study states (CT, MD, MN, and NY). The number of tests and 
percent positive by test type were aggregated across all laboratories. Assay types included 
serologic testing (for all pathogens), direct visualization (babesiosis, HGA, HME), and PCR 
(babesiosis and HGA).
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Non-responding laboratories were sent two follow-up emails. If still no response was 
received, research staff from the EIP in each state contacted laboratory managers in their 
respective states by telephone to request participation and collected survey responses over 
the telephone. Both phases of this research effort were deemed exempt from IRB review 
(non-human subject research) by the Yale Human Investigations Committee and CDC.
Estimating the costs of tickborne disease testing
To estimate the direct cost of non-Lyme disease TBD testing nationally, the proportion of 
assay types used to diagnose specific TBDs reported by the Phase 2 laboratories (e.g., IFA, 
PCR, microscopy) was applied to the national specimen testing volume for each TBD 
reported by the Phase 1 laboratories. The national limit for reimbursement in the 2008 
clinical diagnostic laboratory fee schedule (Centers for Medicare and Medicaid Services, 
2008) was then used to estimate the cost of national testing for the following test types: 
Babesia, Anaplasma or Ehrlichia direct detection (microscopy) ($16.76), Babesia indirect 
fluorescent antibody ($17.32), Babesia or Anaplasma PCR ($49.04), Anaplasma or 
Ehrlichia indirect fluorescent antibody ($14.22), HGA/HME concurrent panel ($28.44), 
RMSF indirect fluorescent antibody ($27.05). Although tickborne relapsing fever and 
Colorado tick fever are not endemic to CT, MD, MN, and NY, the 2008 national limit for 
their diagnostic immunoassays were also applied to the total number of specimens tested 
nationally ($37.38 and $36, respectively).
RESULTS
Phase 1
Six laboratories completed the entire survey: ARUP, Clinical Laboratory Partners, Focus 
Diagnostics, LabCorp, Quest Diagnostics, and Specialty Laboratories. One additional 
laboratory, Mayo Medical Laboratories, completed only the PCR and serology sections of 
the survey. All data were aggregated to protect the identity of each individual laboratory.
National TBD testing volume is reported in Table 1. Of the nearly three million specimens 
tested for tickborne pathogens in 2008, 83 percent of the specimens were tested for Lyme 
disease, followed by HME (6 percent), RMSF (5 percent), babesiosis (3 percent), HGA (2 
percent), tick-borne relapsing fever (<1 percent), and Colorado tick fever (<1 percent). No 
commercial laboratories reported testing for Powassan virus. The details of the Lyme 
disease testing portion of the laboratory survey are reported by Hinckley et al. (2014).
Phase 2
A total of 1,051 laboratories were sent surveys in CT (n=30), MD (n=42), MN (n=158), and 
NY (n=821). In total, 331 laboratories (31 percent) responded to the survey; responding 
laboratories did not always provide responses to all modules in the survey. Responding 
laboratories were self-described as hospital (72 percent), commercial (19 percent), clinical 
(10 percent), governmental (5 percent), or other (6 percent). Response data from the four 
states were aggregated. Detailed results from the Lyme disease module were reported 
separately (Hinckley et al., 2014).
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Babesiosis—Fifty-seven (18 percent) of the 312 laboratories that responded to the 
Babesia module of the survey reported conducting in-house testing for Babesia microti. The 
survey module queried laboratories about assays ordered specifically for Babesia. Therefore, 
incidental diagnoses following review of a blood smear initially ordered for other reasons 
were not part of this module. A total of 4,967 specimens were tested by responding 
laboratories in the four study states. Diagnostic tests conducted by responding laboratories 
included microscopy (72 percent), indirect fluorescent antibody (IFA) (28 percent) and 
polymerase chain reaction (PCR) (< 1 percent). Babesia testing volume and positivity by 
assay are detailed in Table 2.
Anaplasmosis (HGA) and ehrlichiosis (HME)—Thirty-one (10 percent) of the 304 
laboratories that responded to the HGA-HME module of the survey reported conducting in-
house laboratory testing for HGA or HME (or both). A total of 1,218 specimens were tested 
by responding laboratories for Anaplasma phagocytophilum by IFA (47 percent), 
microscopy (41 percent) and PCR (12 percent). A total of 2,530 specimens were tested for 
Ehrlichia chaffeensis by laboratories in the four study states. Most of the specimens were 
tested using IFA (92 percent), and a few were tested via microscopy (8 percent). A small 
number of specimens were tested using a panel for concurrent HGA and HME testing. HGA 
and HME testing volume and positivity by assay are detailed in Table 2.
Rocky Mountain spotted fever (RMSF)—Of the 319 laboratories that responded to the 
RMSF module, four laboratories (1 percent) reported conducting testing for Rickettsia 
rickettsii on site. A total of 1,236 specimens were tested in two states (NY and MD), all by 
IFA, with a 6 percent positivity (Table 2).
Estimated costs of tickborne disease testing
The estimated direct cost for TBDs other than Lyme disease nationally was $9.6 million, 
including $4.1 million for RMSF, $2.8 million for ehrlichiosis, $1.5 million for babesiosis, 
$1.2 million for anaplasmosis, and $0.11 million for HME/HGA panels. Costs for diagnosis 
of tickborne relapsing fever and Colorado tick fever are estimated at $15,000 and $4,000, 
respectively (Table 3).
DISCUSSION
Nearly three million specimens were tested for TBDs by responding large and small 
laboratories in the US in 2008. Eighty-three percent of specimens in our survey were tested 
for Lyme disease. Similarly, Lyme disease accounted for 86 percent of all TBDs reported to 
CDC in 2008 (CDC, 2010). The proportions of laboratory testing volume for RMSF, 
anaplasmosis and ehrlichiosis were similar to the proportions of cases reported to CDC. We 
estimate that the direct costs for the non-Lyme disease TBD tests to total nearly $10 million. 
Including the estimated $492 million estimated cost of Lyme disease testing (Hinckley et al., 
2014), the estimated direct cost of TBD testing in the United States amounts to $501.6 
million. Testing for TBDs other than Lyme disease accounted for approximately 17 percent 
of all tickborne disease testing in 2008. The nearly $10 million cost for non-Lyme disease 
testing is an estimate of what commercial laboratories charged in 2008 according the Center 
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for Medicare and Medicaid Services Clinical Diagnostic Laboratory fee schedule. This 
figure does not include other indirect expenses that may accompany these diagnostic tests 
(Hinckley et al., 2014) and likely underestimates the true cost of TBD testing nationally.
More specimens were tested for ehrlichiosis than for RMSF nationally, despite the fact that 
more than twice the number of RMSF cases were reported to CDC in 2008 than ehrlichiosis 
cases (including E. chaffeensis and E. ewingii) (CDC, 2012). Because the causative agent of 
anaplasmosis was considered to be an Ehrlichia species until 2000, some healthcare 
providers may mistakenly still refer to cases of anaplasmosis as ehrlichiosis and therefore 
order tests for Ehrlichia instead of Anaplasma (Wormser et al., 2006). Alternatively, 
diagnostic assays for Ehrlichia and Anaplasma are often included on the same testing panel. 
Therefore, specimens counted for Ehrlichia testing may be greater in number because they 
include those originally submitted for Anaplasma testing or ordered as part of a panel.
The majority of specimens tested for HGA or HME, as reported in Phase 2 of the study, 
were done using IFA, which is common for the diagnosis of Anaplasma and Ehrlichia 
pathogens (Wormser et al., 2006). Although thought to be uncommon, it is possible that 
both acute and convalescent specimens are tested for some individuals, which may 
contribute to an overestimate in the positivity rate for those tests overall. In addition, a large 
number of specimens were examined by microscopy as a method of pathogen detection. 
This method may be insensitive and may require examination by a microscopist with 
specialized expertise in this field, and may therefore contribute to an underestimate of the 
true positivity rate (Ismail et al., 2010).
RMSF testing was conducted exclusively by IFA in the four study states. IFA was the most 
acceptable method at the time for detection of the causative agent R. rickettsia; however, 
timing of the sample collection is important to the sensitivity of the test (CDC, 2006). It is 
unclear how many of the nearly 2,000 specimens tested included acute and convalescent 
specimens from the same patient, as those data were not collected. Therefore, the positivity 
rate reported in the results may be greatly affected by this issue.
The majority of tests for babesiosis conducted in the four study states were via blood smear 
microscopy. Although microscopy and PCR are the recommended methods for detection of 
Babesia microti (CDC, 2012), the survey of Phase 2 laboratories found that nearly one-third 
of specimens were tested for Babesia parasites using IFA. Less than one percent of 
specimens were tested using PCR. Since the majority of laboratories responding to the Phase 
2 survey modules were hospital-based laboratories, it is not surprising that microscopy 
would be used more commonly than PCR. The Babesia survey module asked about tests 
conducted specifically for detecting Babesia; diagnoses made from incidental detection via 
blood smears were not included as part of the survey.
Our findings illustrate the large volume of TBD testing in the United States. Because not 
every large commercial testing facility that was contacted responded to the Phase 1 survey, 
it is likely that these findings underrepresent the true testing burden for TBDs. However, the 
laboratories that did respond accounted for the majority of Lyme disease testing nationally 
(Hinckley et al., 2014). It is also possible that some laboratories were not identified and 
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therefore not invited to participate in this survey, especially in Connecticut, Maryland, and 
Minnesota, where we targeted the survey based on state disease surveillance records. In 
addition, we did not collect positivity rates for diseases other than Lyme disease during 
Phase 1. Therefore, we cannot compare the positivity rates for TBDs at the Phase 2 
laboratories to national rates.
Similarly, the assay types used to diagnose TBDs during Phase 1 were not collected. Instead, 
the proportion of assay types used by Phase 2 laboratories was applied to Phase 1 data to 
estimate the national distribution of assay type for each TBD. If testing patterns at the large 
commercial laboratories of Phase 1 differ greatly from the smaller commercial and hospital-
based laboratories of Phase 2, our cost estimates may be inaccurate. For example, if large 
commercial laboratories are more likely than smaller clinical laboratories to conduct 
molecular tests for TBDs (e.g., PCR), it is possible that we underestimated the direct costs of 
testing. Additional studies could help elucidate the testing practice differences between the 
types of laboratories surveyed in this study. In addition, using CMS reimbursement rates 
provided us the minimum costs associated with TBD testing. Therefore, we conclude that 
the nearly $10 million cost estimate for non-Lyme TBD testing is a conservative one. We 
are currently unaware of any studies estimating the testing volume and costs for non-Lyme 
TBD testing. This study provides a baseline of testing data for these emerging arthropod-
borne infectious diseases.
If done routinely, laboratory surveillance may present a more efficient and sustainable 
approach than current public health methods (i.e., passive surveillance whereby providers 
and laboratories report cases to public health agencies) for monitoring trends of TBD in the 
U.S. However, because positive antibody tests may only indicate exposure to a pathogen and 
can be falsely positive in some circumstances, it is unclear how many active infections, as 
indicated by incident TBD cases captured through current public health surveillance 
methods, could be ascertained through laboratory surveillance alone. Nevertheless, the 
results of this survey provide valuable insight into the true magnitude and costs of these 
diseases and give us a baseline to evaluate trends in TBD test utilization and positivity in the 
United States.
ACKNOWLEDGEMENTS
We thank Barbara Herwaldt and Patty Wilkins for guidance on Babesia questions and interpretation; Jennifer 
McQuiston and William Nicholson for guidance on rickettsial agent questions and interpretation. We also thank 
Paula Snippes Vagnone for helping coordinate survey distribution in Minnesota. This work would not have been 
possible without Erin Jones at the Maryland Department of Health, as well as several Yale MPH students, and 
graduate student workers in the Minnesota Department of Health Vector-Borne Disease program who also assisted 
with data collection. This work was supported by CDC Cooperative Agreements to the Connecticut, Maryland, 
Minnesota, and New York Emerging Infections Programs. (Cooperative Agreement # 5U01CI000307 [CT], 
5U01CI00031005 [MD], 5U01C1000313 [MN], 5U01CI00031004 [NY]).
REFERENCES
Associates, MK. Projected annual market for rapid direct tests. Owings Mills, MD: Rapid testing for 
infectious diseases: competitive advantage in a turbulent market; 1993. p. 277
Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial 
diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis -- United States. Morb 
Mortal Wkly Rep. 2006; 55
Connally et al. Page 7













Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2008. 
Morb Mortal Wkly Rep. 2010; 54:1–94.
Centers for Disease Control and Prevention. Babesiosis surveillance-- 18 states, 2011. Morb Mortal 
Wkly Rep. 2012; 61:505–509.
Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2010. 
Morb Mortal Wkly Rep. 2012; 9:2–111.
Centers for Medicare and Medicaid Services. [Accessed May 29, 2015] Current Procedural 
Terminology (CPT). Fourth Edition2008. http://www.cms.gov/apps/ama/license.asp?file=/
ClinicalLabFeeSched/downloads/08clab-b.zip.
Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, Mead 
PS. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 
2014; 59:676–681. [PubMed: 24879782] 
Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin Lab Med. 2010; 
30:262–291.
Ramsey A, Belongia E, Chyou PH, Davis J. The appropriateness of Lyme disease serologic testing. 
Ann Family Med. 2004; 2:341–344.
Tugwell P, Dennis D, Weinstein A, Wells G, Shea B, Nichol G, et al. Laboratory evaluation in the 
diagnosis of Lyme disease. Ann Intern Med. 1997; 127:1109–1123. [PubMed: 9412316] 
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken 
JS, Strle F, Standek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, 
treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: 
clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 
43:1089–1134. [PubMed: 17029130] 
Connally et al. Page 8














A two-phased laboratory survey approach for non-Lyme tickborne disease testing.
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Table 1
Testing volume for tick-borne diseases in the US, 20081
Tickborne Disease Specimens Tested %
Lyme disease 2,432,396 83
Ehrlichiosis (HME) 193,121 6
Rocky Mountain spotted fever 152,713 5
Babesiosis 85,323 3
Anaplasmosis (HGA) 59,943 2
HGA/HME2 3,750 <1
Tick-borne relapsing fever 405 <1
Colorado tick fever 230 <1
Powassan encephalitis 0 0
Total 2,927,881
1
Data aggregated from seven U.S. commercial laboratories.
2
One laboratory could not provide data specific to Anaplasma vs. Ehrlichia PCR testing.
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Table 2
Tickborne disease testing volume and positivity in four states, by diagnostic assay, 2008.
Tickborne disease No. Tests No. Positive
(%)
Babesiosis Microscopy (DFM, Giemsa-Wright or Wright) 3,561 71 (2)
IFA 1,388 28 (2)
PCR (blood, serum, CSF) 18 1 (6)
Total 4,967
Anaplasmosis (HGA) IFA 575 40 (7)
Microscopy (Giemsa-Wright) 493 44 (9)
PCR (blood) 150 1 (8)
Total HGA 1,218
Ehrlichiosis (HME) IFA 2,326 19 (8)
Microscopy (Giemsa-Wright) 204 0 (0)
Total HME 2,530
HGA/HME Concurrent Panel 120 5 (4)
Rocky Mountain spotted fever (RMSF) IFA 1,236 74 (6)
*
Data from small clinical and hospital laboratories testing specimens in CT, MD, MN, and NY in 2008. Does not reflect specimens tested by large, 
commercial laboratories.
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Table 3














Babesiosis Microscopy 3,561 (71.7) 61,177 1,025,320
IFA 1,388 (27.9) 23,805 412,305
PCR 18 (0.4) 341 16,737
    Total 4967 85,323 1,454,362
Anaplasmosis (HGA) Microscopy 493 (40.5) 24,277 406,881
IFA 575 (47.2) 28,293 402,328
PCR 150 (12.3) 7,373 361,571
    Total 1218 59,943 1,170,780
Ehrlichiosis (HME) Microscopy 204 (8.1) 15,643 262,173
IFA 2,326 (91.9) 177,478 2,523,739
    Total 2530 193,121 2,785,912
HGA/HME Concurrent Panel 120 (100) 3,750 106,650
    Total 120 3,750 106,650
Rocky Mountain Spotted Fever IFA 1,236 (100) 152,713 4,130,887
    Total 1236 152,713 4,130,887
Tick-borne Relapsing Fever IFA 405 15,139
    Total 405 15,139
Colorado Tick Fever IFA 230 8,280
    Total 230 8,280
  TOTAL 9,672,010
*
Specimens tested from CT, MD, MN, and NY in 2008. Because specimens in these states were not tested for tick-borne relapsing fever or 
Colorado tick fever, estimates were based upon the national limit for CMS costs in 2008.
Ticks Tick Borne Dis. Author manuscript; available in PMC 2017 February 01.
